Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mitoxantrone
Drug ID BADD_D01480
Description An anthracenedione-derived antineoplastic agent.
Indications and Usage For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Marketing Status Prescription; Discontinued
ATC Code L01DB07
DrugBank ID DB01204
KEGG ID D08224
MeSH ID D008942
PubChem ID 4212
TTD Drug ID D0R3JB
NDC Product Code 61703-343; 0703-4685; 0703-4686; 0703-4680
Synonyms Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone
Chemical Information
Molecular Formula C22H28N4O6
CAS Registry Number 65271-80-9
SMILES C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ApoptosisTranscription factor JunP05412T690858219202; 1450413; 9816016; 7683227; 8096557; 8243566; 8260751; 7915211; 9581849
ApoptosisG1/S-specific cyclin-D1P24385T123558219202; 1450413; 9816016; 7683227; 8096557; 8243566; 8260751; 7915211; 9581849
Cytogenetic investigationsDNA topoisomerase 1P11387T098261997159; 1649059; 1333822; 1540962; 1596908; 1330289; 8382551; 2168279; 2168281; 1319346; 11062742; 1374671; 1646393; 7882360; 1322239; 7688316; 1659821; 8383887; 8144400; 1698546
Toxicity to various agentsEpoxide hydrolase 1P07099Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Breast cancer21.05.01.003; 16.10.01.0010.000533%Not Available
Breast cancer stage IV21.05.01.010; 16.10.01.003--Not Available
Cardiac failure02.05.01.0010.000278%
Cardiac failure congestive02.05.01.0020.000799%Not Available
Cardiogenic shock02.05.01.003; 24.06.02.0060.000139%Not Available
Cardiomyopathy02.04.01.0010.001598%Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.001--Not Available
Catheterisation cardiac abnormal13.14.07.001--Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.02.08.003--Not Available
Chills15.05.03.016; 08.01.09.001--
Chromaturia20.02.01.002--
Chromosome banding abnormal13.22.02.001--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis06.04.01.002; 11.01.06.012--
Constipation07.02.02.001--
Cough22.02.03.001--
Death08.04.01.001--
Dehydration14.05.05.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.0010.000799%
Discomfort08.01.08.003--Not Available
Dysgeusia07.14.03.001; 17.02.07.003--
Dyspepsia07.01.02.001--
Dyspnoea22.02.01.004; 02.01.03.0020.000799%
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Electrocardiogram abnormal13.14.05.001--Not Available
Electrocardiogram T wave inversion13.14.05.0070.000533%Not Available
Endocrine disorder05.09.01.001--Not Available
Endometritis21.14.01.002; 11.01.10.005--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 8 Pages